Document is current

Any future updates will be listed below

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Crossref DOI link: https://doi.org/10.1007/s40120-024-00648-z

Published Online: 2024-08-06

Published Print: 2024-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark